vs
AC Immune SA（ACIU）与阿斯利康（AZN）财务数据对比。点击上方公司名可切换其他公司
阿斯利康的季度营收约是AC Immune SA的10063.3倍（$14.5B vs $1.4M）。阿斯利康净利率更高（16.9% vs -1622.4%，领先1639.4%）。AC Immune SA同比增速更快（90.1% vs 11.7%）
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
ACIU vs AZN — 直观对比
营收规模更大
AZN
是对方的10063.3倍
$1.4M
营收增速更快
ACIU
高出78.4%
11.7%
净利率更高
AZN
高出1639.4%
-1622.4%
损益表 — Q2 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4M | $14.5B |
| 净利润 | $-23.3M | $2.4B |
| 毛利率 | — | 82.9% |
| 营业利润率 | -1484.5% | 24.3% |
| 净利率 | -1622.4% | 16.9% |
| 营收同比 | 90.1% | 11.7% |
| 净利润同比 | 6.9% | 27.0% |
| 每股收益（稀释后） | — | $1.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACIUAZN
| Q2 25 | $1.4M | $14.5B | ||
| Q2 24 | $755.7K | $12.9B | ||
| Q2 23 | — | $11.4B | ||
| Q3 22 | $4.3M | — | ||
| Q2 22 | — | $10.8B |
净利润ACIUAZN
| Q2 25 | $-23.3M | $2.4B | ||
| Q2 24 | $-25.0M | $1.9B | ||
| Q2 23 | — | $1.8B | ||
| Q3 22 | $-14.9M | — | ||
| Q2 22 | — | $360.0M |
毛利率ACIUAZN
| Q2 25 | — | 82.9% | ||
| Q2 24 | — | 83.1% | ||
| Q2 23 | — | 82.8% | ||
| Q3 22 | — | — | ||
| Q2 22 | — | 72.2% |
营业利润率ACIUAZN
| Q2 25 | -1484.5% | 24.3% | ||
| Q2 24 | -3051.1% | 21.2% | ||
| Q2 23 | — | 21.5% | ||
| Q3 22 | -342.2% | — | ||
| Q2 22 | — | 5.0% |
净利率ACIUAZN
| Q2 25 | -1622.4% | 16.9% | ||
| Q2 24 | -3313.0% | 14.9% | ||
| Q2 23 | — | 15.9% | ||
| Q3 22 | -343.6% | — | ||
| Q2 22 | — | 3.3% |
每股收益（稀释后）ACIUAZN
| Q2 25 | — | $1.57 | ||
| Q2 24 | — | $1.24 | ||
| Q2 23 | — | $1.17 | ||
| Q3 22 | — | — | ||
| Q2 22 | — | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.3M | $7.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $82.2M | $44.8B |
| 总资产 | $209.2M | $112.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACIUAZN
| Q2 25 | $28.3M | $7.1B | ||
| Q2 24 | $56.7M | $6.9B | ||
| Q2 23 | — | $5.7B | ||
| Q3 22 | $49.0M | — | ||
| Q2 22 | — | $4.8B |
股东权益ACIUAZN
| Q2 25 | $82.2M | $44.8B | ||
| Q2 24 | $135.8M | $39.6B | ||
| Q2 23 | — | $37.4B | ||
| Q3 22 | $209.1M | — | ||
| Q2 22 | — | $36.0B |
总资产ACIUAZN
| Q2 25 | $209.2M | $112.4B | ||
| Q2 24 | $261.3M | $104.3B | ||
| Q2 23 | — | $96.5B | ||
| Q3 22 | $226.1M | — | ||
| Q2 22 | — | $96.6B |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
